Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Externally Developed Products Mean Bigger Revenues, But Not In Diabetes

Executive Summary

External innovation directly links to commercial success for big pharma, and will continue to do so until 2026, according to a new report by Datamonitor Healthcare.

You may also be interested in...



Lilly Pays KeyBioscience $55m Up Front to Expand Its Early Diabetes Pipeline

Lilly nabbed multiple molecules for its early-stage diabetes portfolio via a $55m-plus partnership with KeyBioscience, making sure that the big pharma's pipeline continues to add products to its largest franchise.

Sanofi, Google’s Verily Enter Diabetes JV To Produce Joined Up Solutions

Sanofi’s diabetes head says French drug maker’s JV pact with Google’s Verily will combine novel therapies for the condition with cutting edge technologies to produce better focused, outcome-based combinations.

A New Generation Invents Pharma’s Mirrored Future

Young businesses are getting set to disrupt every inch of the healthcare space with digital twin technology. Outlook spoke to two startups on the brink of a data dawn.

Topics

Related Companies

UsernamePublicRestriction

Register

SC123250

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel